Evidence map›Paper›PMID 37522353›Full record

ArticleCardiovascular research2023

FAM210A regulates mitochondrial translation and maintains cardiac mitochondrial homeostasis.

Jiangbin Wu, Kadiam C Venkata Subbaiah, Omar Hedaya, Si Chen, Joshua Munger, Wai Hong Wilson Tang, Chen Yan, Peng Yao

Open access · greenAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. FAM210A: An emerging regulator of mitochondrial homeostasis.BioEssays : news and reviews in molecular, cellular and developmental biology · 2024
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiangbin WuAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.ORCID 0000-0003-3109-417X
Kadiam C Venkata SubbaiahAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Omar HedayaAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Si ChenAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Joshua MungerDepartment of Biochemistry & Biophysics, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Wai Hong Wilson TangDepartment of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
Chen YanAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.ORCID 0000-0002-1397-6358
Peng YaoAab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA.ORCID 0000-0002-1145-3967
University of Rochester · USCleveland Clinic · US

Funding

Training in Cellular, Biochemical and Molecular SciencesT32GM068411 · NIGMS · UNIVERSITY OF ROCHESTER · PI MAQUAT, LYNNE E · 2005 to 2019
$3.9M
Metabolic modulation by the HCMV UL38 geneR01AI150698 · NIAID · UNIVERSITY OF ROCHESTER · PI JOSHUA C MUNGER · 2020 to 2026
$2.4M
Regulation and Function of Cyclic Nucleotide Phosphodiesterase in Cardiac Biology and DiseaseR01HL154318 · NHLBI · UNIVERSITY OF ROCHESTER · PI YAN, CHEN · 2021 to 2024
$2.1M
uORF-mediated Translational Control of Cardiac Transcription Factor ExpressionR01HL164584 · NHLBI · UNIVERSITY OF ROCHESTER · PI Peng Yao · 2023 to 2026
$2.0M
HCMV-mediated repurposing of AMPK & CaMKK signaling for productive infectionR01AI127370 · NIAID · UNIVERSITY OF ROCHESTER · PI MUNGER, JOSHUA C · 2016 to 2020
$1.9M
Deciphering the role of FAM210A in cardiac physiopathologyR01HL169432 · NHLBI · UNIVERSITY OF ROCHESTER · PI Peng Yao · 2023 to 2026
$1.9M
Translational Control of Cardiac FibrosisR01HL147954 · NHLBI · UNIVERSITY OF ROCHESTER · PI YAO, PENG · 2019 to 2022
$1.5M
Role of miR-574-Fam210a axis in cardiac hypertrophy and remodelingR01HL132899 · NHLBI · UNIVERSITY OF ROCHESTER · PI YAO, PENG · 2018 to 2021
$1.5M
NHLBI NIH HHS R01 HL132899NHLBI NIH HHS R01 HL147954NHLBI NIH HHS R01 HL154318NHLBI NIH HHS R01 HL164584NHLBI NIH HHS R01 HL169432NIAID NIH HHS R01 AI127370NIAID NIH HHS R01 AI150698NIGMS NIH HHS T32 GM068411
6 · The paper itself

Abstract

aimsMitochondria play a vital role in cellular metabolism and energetics and support normal cardiac function. Disrupted mitochondrial function and homeostasis cause a variety of heart diseases. Fam210a (family with sequence similarity 210 member A), a novel mitochondrial gene, is identified as a hub gene in mouse cardiac remodelling by multi-omics studies. Human FAM210A mutations are associated with sarcopenia. However, the physiological role and molecular function of FAM210A remain elusive in the heart. We aim to determine the biological role and molecular mechanism of FAM210A in regulating mitochondrial function and cardiac health in vivo. METHODS AND

resultsTamoxifen-induced αMHCMCM-driven conditional knockout of Fam210a in the mouse cardiomyocytes induced progressive dilated cardiomyopathy and heart failure, ultimately causing mortality. Fam210a deficient cardiomyocytes exhibit severe mitochondrial morphological disruption and functional decline accompanied by myofilament disarray at the late stage of cardiomyopathy. Furthermore, we observed increased mitochondrial reactive oxygen species production, disturbed mitochondrial membrane potential, and reduced respiratory activity in cardiomyocytes at the early stage before contractile dysfunction and heart failure. Multi-omics analyses indicate that FAM210A deficiency persistently activates integrated stress response, resulting in transcriptomic, translatomic, proteomic, and metabolomic reprogramming, ultimately leading to pathogenic progression of heart failure. Mechanistically, mitochondrial polysome profiling analysis shows that FAM210A loss of function compromises mitochondrial mRNA translation and leads to reduced mitochondrial-encoded proteins, followed by disrupted proteostasis. We observed decreased FAM210A protein expression in human ischaemic heart failure and mouse myocardial infarction tissue samples. To further corroborate FAM210A function in the heart, AAV9-mediated overexpression of FAM210A promotes mitochondrial-encoded protein expression, improves cardiac mitochondrial function, and partially rescues murine hearts from cardiac remodelling and damage in ischaemia-induced heart failure.

conclusionThese results suggest that FAM210A is a mitochondrial translation regulator to maintain mitochondrial homeostasis and normal cardiomyocyte contractile function. This study also offers a new therapeutic target for treating ischaemic heart disease.

Indexed as

Heart FailureVentricular RemodelingAnimalsHomeostasisHumansMiceMice, KnockoutMitochondria, HeartMitochondrial ProteinsMyocytes, CardiacProteomicsFam210a protein, mouseMitochondrial ProteinsCardiomyopathyFAM210AHeart failureIntegrated stress responseMetabolismMitochondriamRNA translationMyocardial infarction

Identifiers

PMID37522353
PMCPMC10651191
OpenAlexW4385406192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.